Tirzepatide Cost: Monthly Prices, Insurance, and Savings

If you're considering tirzepatide for weight loss or type 2 diabetes, the price tag is probably one of your first concerns. Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for weight management, and monthly costs can range from under $25 to well over $1,000 depending on your insurance status, dose, and where you fill your prescription. This guide breaks down every cost scenario, savings strategy, and coverage pathway so you can make an informed decision.

Quick Take: Typical Monthly Cost

Without insurance, tirzepatide costs approximately $1,080 to over $1,300 per month at retail pharmacies for brand-name single dose pens or multi dose pens. Cash-pay prices for tirzepatide vary widely based on pharmacy and dose, so shopping around matters.

Here's a snapshot of what you might pay:

Zepbound vials cost $299 to $449 per month through LillyDirect, making them a significantly more affordable option for self pay patients. Note that clinician fees, lab work, shipping, and supplies are typically separate from the medication price itself.

Cost Scenarios: With Insurance Versus Without

Your final monthly costs will vary depending on your insurance, diagnosis, and chosen formulation.

With commercial insurance: When your plan covers tirzepatide and you qualify for a manufacturer savings card, commercial insurance can reduce tirzepatide costs to about $25 per month. Even moderate coverage scenarios typically leave patients paying $50–$300 monthly, depending on formulary tier and coinsurance rates. Provider visits may be covered by many commercial plans along with Medicare and Medicaid.

Without insurance: In New York City, the retail price for tirzepatide typically ranges from $1,000 to $1,200 per month without insurance-and similar list price ranges apply nationwide. Without insurance, self-pay prices for Zepbound typically range from $250 to $400+ per month when using Eli Lilly's vial programs rather than brand pens.

Medicaid: Medicaid copays for tirzepatide range from $0 to $10 for covered indications. Monthly costs with Medicaid can range from $0 to $10 since Medicaid typically offers lower copays for diabetes coverage. However, weight management coverage through Medicaid remains limited in most states.

Medicare: Mounjaro is covered under Medicare Part D for type 2 diabetes. Zepbound for weight loss is generally excluded under current Medicare policy.

Insurance Coverage and Prior Authorization

Insurance coverage for tirzepatide varies by diagnosis and plan. For type 2 diabetes, most insurance plans are more likely to include Mounjaro on their formularies. Coverage for weight loss using Zepbound is highly variable and depends on the employer's plan-roughly 30–40% of large commercial insurance plans covered Zepbound as of mid-2026. Insurance coverage varies widely based on the prescribed indication, so confirming your specific benefit is essential.

Zepbound is less likely to be covered for weight loss than for diabetes. Many plans in New York City cover tirzepatide with prior authorization required, and this pattern holds across major metro areas.

Common insurance limitations include:

• Explicit exclusion of weight loss medications from formularies

• BMI thresholds (≥30, or ≥27 with comorbidities like high blood pressure or high cholesterol)

• Mandatory documentation of failed lifestyle interventions over 3–6 months

• Dose escalation requirements aligned with FDA-approved labels

• Annual or lifetime fill limits for obesity treatments

Check your plan's formulary directly by searching for "Zepbound," "tirzepatide," or "GLP-1" to confirm whether your plan covers the medication for your specific diagnosis.

Prior Authorization: Common Requirements

Prior authorization is often required for tirzepatide coverage. Insurers typically request:

• BMI measurement meeting threshold criteria

• Medical history documenting comorbid conditions (obstructive sleep apnea, hypertension, dyslipidemia)

• Evidence of prior weight loss attempts through a reduced calorie diet and exercise over at least 3–6 months

• Relevant labs (HbA1c, fasting glucose, metabolic panel)

• List of current medications and other medications tried

Sample prior authorization language for clinicians:

"Patient is a [age]-year-old with BMI of [XX] and obesity comorbidity [e.g., sleep apnea, hypertension], who has attempted lifestyle intervention including diet and exercise for at least 3 months without clinically significant weight loss. No contraindications to GLP-1/GIP receptor agonist therapy. Prior treatments: [list]. Labs: [HbA1c/glucose]. Weight history documented."

Recommend documenting dose adjustments and treatment response at each step-this strengthens both initial approval and future appeals.

Manufacturer Savings, Eligibility Requirements, and News Release

Eli Lilly's savings card can reduce costs to $25 per month for eligible patients with commercial insurance plans that cover the medication. Manufacturer savings cards can reduce costs to $25 per month, but they only apply after your insurer approves coverage.

The Zepbound self-pay program offers vials for $349 to $499 per month through LillyDirect for patients paying cash or whose insurance doesn't cover the drug. Zepbound vials cost $349 to $499 through Lilly's self-pay program, depending on dose.

Eligibility requirements for savings programs:

• Must have commercial insurance (federal programs like Medicare and Medicaid are excluded)

• Drug must be covered by your plan for the savings card to apply

• Valid prescription required

Patient assistance programs may cover medication costs entirely for patients who meet income thresholds-check Lilly's website for current qualification criteria.

In a recent news release, Eli Lilly announced lower prices for Zepbound single dose vial formulations, citing the need to improve accessibility and reduce cost barriers for obesity treatment.

Compounded Tirzepatide: Pricing and Considerations

Compounded tirzepatide is prepared by licensed compounding pharmacies and contains the same active ingredient as brand-name versions. These formulations typically come as multi-dose vials rather than prefilled pens, and they're produced under state compounding regulations.

Compounded tirzepatide costs between $250 and $500 per month, with lower doses at the lower end and higher maintenance doses pushing toward $500. Compounded tirzepatide averages $250 to $500 per month across most telehealth platforms and compounding providers. Compounded tirzepatide is often more accessible than brand-name options for patients who can't access or afford brand pricing.

However, compounded medications are not FDA approved for safety or effectiveness. After FDA removed tirzepatide from the drug shortage list in late 2024, mass compounding through 503B outsourcing facilities was restricted. Compounding is now limited to patient-specific 503A prescriptions.

Before choosing a compounding pharmacy, verify state licensing, USP sterile compounding compliance, and any third-party quality certifications. A serious allergic reaction or allergic reaction risk exists with any injectable, so work with licensed providers who can monitor your treatment.

Personalized Dosing: Gradually Increased Protocols

Tirzepatide follows a gradually increased dosing protocol:

1. Start: 2.5 mg once weekly (low dose) for 4 weeks

2. Escalate: Increase to 5 mg, then 7.5 mg, then 10 mg every 4 weeks

3. Maintenance: Up to 15 mg weekly, depending on tolerability and response

This personalized dosing approach means your monthly costs will shift as you move through escalation. Through LillyDirect, a 2.5 mg vial might cost $299, while a 15 mg single dose vial could reach $499 or more. Compounded options tend to have flatter pricing across dose tiers, though higher-dose maintenance often increases cost modestly.

Document every dose change and your body's response-this record helps your healthcare provider support prior authorization requests and appeals at each escalation step.

Clinical Trials, GLP 1, and Cost-Effectiveness

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and demonstrated mean weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. About 57% of participants on the highest dose lost 20% or more of their body weight-results that reshape how we think about weight loss medications.

Tirzepatide works as a dual-action GLP 1 and GIP receptor agonist, which contributes to more potent results compared to GLP 1-only treatments like semaglutide. Extended follow-up showed a 94% reduction in risk of progressing from pre-diabetes to type 2 diabetes-critical for blood sugar control.

On cost-effectiveness, a 2025 model published in JAMA Health Forum estimated that the net price would need to drop roughly 30.5% to reach the standard $100,000-per-QALY threshold. This suggests the list price remains high relative to long-term value, though transparent pricing initiatives and lower prices through vial programs are closing the gap.

Chronic Weight Management: How Tirzepatide Helps Lose Weight

Tirzepatide is FDA approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It works by targeting how the body stores fat and regulates blood sugar, reducing appetite and helping patients lose weight when combined with a reduced calorie diet and increased physical activity. Understanding how the body stores energy helps explain why this dual receptor agonist approach produces superior results.

Set realistic expectations: full titration takes about 20 weeks, and maximum efficacy emerges around 72 weeks. Stopping the medication typically leads patients to regain weight, so treatment is generally long-term. That means budgeting for monthly refills at your maintenance dose over years, not just months.

Obstructive Sleep Apnea and Coverage Implications

Obstructive sleep apnea is one of the most common comorbidities linked to obesity, and SURMOUNT-1 included it as a qualifying condition for patients with BMI ≥27. Documenting a sleep apnea diagnosis with a sleep study and AHI score strengthens your prior authorization package significantly.

Many prior authorization requirements explicitly ask whether the patient has conditions like obstructive sleep apnea. If you have this diagnosis, make sure your nurse practitioner or physician includes it in every coverage request.

How To Get a Prescription Without Insurance

Telehealth: Many telehealth platforms now offer tirzepatide prescribing for weight management. These services connect you with licensed providers who can evaluate your medical history, prescribe the medication, and coordinate with compounding or retail pharmacies. Some bundle physician fees, supplies, and shipping into one monthly price. Always verify the provider is licensed in your state.

In-person: Visit a primary care physician, endocrinologist, or obesity medicine specialist. Expect standard clinic visit fees ($100–$300 for self pay). Your clinician writes the prescription, and you choose your pharmacy. This route is ideal if you need comprehensive medical care or have other factors requiring in-person evaluation.

Pharmacy Shopping and Monthly Cost Optimization

Don't fill your prescription at the first pharmacy you visit. Prices at retail pharmacies like CVS, Walgreens, Walmart, and Costco can differ by $50–$100+ for the same brand product. Discount cards can help find lower prices at local pharmacies-tools like GoodRx may shave a few percentage points off brand pricing, though the savings are modest on a $1,000+ medication.

For the most affordable option when paying cash, check LillyDirect's self pay program for Zepbound vials, which offer lower prices than standard multi dose kwikpen formulations. Cash prices at independent pharmacies sometimes undercut chains, so call around.

Prior Authorization Denials: Appeals and Next Steps

If your prior authorization gets denied:

1. Request the written denial reason from your insurer-usually it's missing BMI documentation, insufficient proof of lifestyle intervention, or formulary exclusion

2. Compile supporting clinical notes: weight history, comorbidity records, lab results, and documentation of prior treatment attempts

3. Obtain a specialist support letter from an endocrinologist or obesity medicine physician referencing clinical trials like SURMOUNT-1

4. Request a peer-to-peer review where your clinician speaks directly with the insurer's medical director

Off label use or diagnosis mismatches are common denial triggers-ensure the prescribed indication matches what your insurance plans cover.

FAQ and Practical Checklist

Does dose matter for cost? Yes. Higher doses increase cost across virtually all pricing paths. Expect monthly costs to rise as your dose is gradually increased during titration.

Pen versus vial-what's cheaper? Single dose pens and multi dose pens are more expensive than Zepbound vials. Vials require syringe administration but offer significantly lower prices.

Does Medicare cover Zepbound? Generally, no. Medicare Part D covers Mounjaro for type 2 diabetes but excludes Zepbound for obesity.

Is compounded tirzepatide safe? It contains the same active ingredient but is not FDA approved. Supply chain oversight and sterility standards vary. Always verify pharmacy credentials. Patients with a history of medullary thyroid carcinoma should discuss risks with their healthcare provider before starting any tirzepatide formulation.

Cost Checklist

• [ ] Confirm your indication (diabetes vs. weight management)

• [ ] Check your insurance formulary for tirzepatide coverage

• [ ] Review prior authorization requirements with your healthcare provider

• [ ] Apply for manufacturer savings programs if you have commercial insurance

• [ ] Compare cash prices at multiple pharmacies

• [ ] Evaluate LillyDirect self pay program for Zepbound vials

• [ ] Consider compounded tirzepatide through a licensed 503A pharmacy

• [ ] Budget for clinician fees, lab work, and supplies separately

• [ ] Document your medical history, BMI, and comorbidities thoroughly

• [ ] Plan for long-term maintenance costs, not just the first few months

The path to making tirzepatide affordable starts with understanding your options. Whether you access tirzepatide through commercial insurance, a self pay program, or compounded medications, the savings add up when you know where to look. Talk to your healthcare provider, check your formulary, and use the checklist above to build your plan.

Frequently Asked Questions

What is the typical monthly cost of tirzepatide without insurance?

Without insurance, brand-name tirzepatide costs approximately $1,000 to $1,300 per month at retail pharmacies. Zepbound vials through LillyDirect are more affordable at $299 to $449 monthly. Compounded tirzepatide ranges from $250 to $500 per month.

How much will I pay with commercial insurance and a savings card?

With commercial insurance coverage and Eli Lilly's manufacturer savings card, monthly costs can be as low as $25. Moderate coverage scenarios typically result in patient costs of $50 to $300 monthly, depending on your plan's formulary tier and coinsurance rates.

What are common prior authorization requirements for tirzepatide coverage?

Insurers typically require BMI measurements meeting threshold criteria, medical history documenting comorbid conditions, evidence of failed lifestyle interventions over 3-6 months, relevant labs like HbA1c and fasting glucose, and a current medication list before approving tirzepatide coverage.

Is tirzepatide covered by Medicare and Medicaid?

Mounjaro for type 2 diabetes is covered under Medicare Part D. Zepbound for weight loss is generally excluded from Medicare. Medicaid copays for tirzepatide range from $0 to $10 for covered indications, though weight management coverage remains limited in most states.

What percentage of commercial insurance plans cover Zepbound for weight loss?

Roughly 30-40% of large commercial insurance plans covered Zepbound for weight loss as of mid-2026. Coverage varies significantly by employer plan and diagnosis, with type 2 diabetes coverage being more common than weight loss coverage.